EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback